Sequential array comparative genomic hybridization analysis identifies copy number changes during blastic transformation of chronic myeloid leukemia

Leukemia Research

Volumn 36, Issue 4, 2012, Pages 418-421

  Lee, Seung Tae ^a,b   Ji, Yongick ^b   Kim, Hee Jin ^a   Ki, Chang Seok ^a   Jung, Chul Won ^a   Kim, Jong Won ^a,b   Kim, Sun Hee ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Samsung Medical Center   (South Korea)

Author keywords

Array CGH; Blastic phase; Chronic myeloid leukemia; MLLT3; PAX5

Indexed keywords

IMATINIB; MLLT3 PROTEIN; PROTEIN; TRANSCRIPTION FACTOR PAX5; UNCLASSIFIED DRUG;

ABL1 GENE; ACUTE LYMPHOBLASTIC LEUKEMIA; ARF4 GENE; ARTICLE; B CELL ACUTE LYMPHOBLASTIC LEUKEMIA; B CELL LEUKEMIA; BACH2 GENE; BAG1 GENE; BCR GENE; BLAST TRANSFORMATION; CANCER GROWTH; CASE REPORT; CDKN2A GENE; CDKN2B GENE; CHROMOSOME 14Q; CHROMOSOME 19P; CHROMOSOME 3P; CHROMOSOME 6Q; CHROMOSOME 7P; CHROMOSOME 7Q; CHROMOSOME 9P; CHROMOSOME ABERRATION; CHROMOSOME BREAKAGE; CHROMOSOME DELETION; CHROMOSOME LOSS; CHRONIC MYELOID LEUKEMIA; COMPARATIVE GENOMIC HYBRIDIZATION; COPY NUMBER VARIATION; DAD1 GENE; EPHA7 GENE; EXON; FAM116A GENE; FANCG GENE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; FOXO3 GENE; FUSION GENE; GENE; GENE DELETION; HADC2 GENE; HIGH RESOLUTION ARRAY COMPARATIVE GENOMIC HYBRIDIZATION; HUMAN; HUMAN CELL; IKZF1 GENE; KARYOTYPE; KARYOTYPE 46,XX; KARYOTYPE 46,XY; LCA5 GENE; LONGITUDINAL STUDY; LPPR3 GENE; MAP3K7 GENE; METAPHASE CHROMOSOME; MLLT3 GENE; MTRNR2L6 GENE; NT5DC1 GENE; PAX5 GENE; PRIORITY JOURNAL; PROMOTER REGION; PRSS1 GENE; PRSS2 GENE; PRUNE2 GENE; PTBP1 GENE; RMRP GENE; STOML2 GENE; TARP GENE; TEK GENE; TOPORS GENE; TRY6 GENE; WISP3 GENE; ZFAND3 GENE;

B-CELL-SPECIFIC ACTIVATOR PROTEIN; BLAST CRISIS; COMPARATIVE GENOMIC HYBRIDIZATION; GENE DOSAGE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; NUCLEAR PROTEINS;

EID: 84862793210     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.12.021     Document Type: Article

References (20)

1. Melo J.V., Barnes D.J. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer 2007, 7:441-453.
2. Hochhaus A., O'Brien S.G., Guilhot F., Druker B.J., Branford S., Foroni L., et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009, 23:1054-1061.
3. Druker B.J., Guilhot F., O'Brien S.G., Gathmann I., Kantarjian H., Gattermann N., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006, 355:2408-2417.
4. Radich J.P. The biology of CML blast crisis. Hematology Am Soc Hematol Educ Program 2007, 384-391.
5. Perrotti D., Jamieson C., Goldman J., Skorski T. Chronic myeloid leukemia: mechanisms of blastic transformation. J Clin Invest 2010, 120:2254-2264.
6. Johansson B., Fioretos T., Mitelman F. Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol 2002, 107:76-94.
7. Mullighan C.G., Miller C.B., Radtke I., Phillips L.A., Dalton J., Ma J., et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 2008, 453:110-114.
8. Nacheva E.P., Brazma D., Virgili A., Howard-Reeves J., Chanalaris A., Gancheva K., et al. Deletions of immunoglobulin heavy chain and T cell receptor gene regions are uniquely associated with lymphoid blast transformation of chronic myeloid leukemia. BMC Genomics 2010, 11:41.
9. Johnson E., Cotter F.E. Monosomy 7 and 7q-associated with myeloid malignancy. Blood Rev 1997, 11:46-55.
10. Vieira S.A., Deininger M.W., Sorour A., Sinclair P., Foroni L., Goldman J.M., et al. Transcription factor BACH2 is transcriptionally regulated by the BCR/ABL oncogene. Genes Chromosomes Cancer 2001, 32:353-363.
11. Saiya-Cork K., Collins R., Parkin B., Ouillette P., Kuizon E., Kujawski L., et al. A pathobiological role of the insulin receptor in chronic lymphocytic leukemia. Clin Cancer Res 2011, 17:2679-2692.
12. Mullighan C.G., Goorha S., Radtke I., Miller C.B., Coustan-Smith E., Dalton J.D., et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 2007, 446:758-764.
13. Nebral K., Denk D., Attarbaschi A., Konig M., Mann G., Haas O.A., et al. Incidence and diversity of PAX5 fusion genes in childhood acute lymphoblastic leukemia. Leukemia 2009, 23:134-143.
14. Kawamata N., Ogawa S., Zimmermann M., Niebuhr B., Stocking C., Sanada M., et al. Cloning of genes involved in chromosomal translocations by high-resolution single nucleotide polymorphism genomic microarray. Proc Natl Acad Sci U S A 2008, 105:11921-11926.
15. An Q., Wright S.L., Konn Z.J., Matheson E., Minto L., Moorman A.V., et al. Variable breakpoints target PAX5 in patients with dicentric chromosomes: a model for the basis of unbalanced translocations in cancer. Proc Natl Acad Sci U S A 2008, 105:17050-17054.
16. Bousquet M., Broccardo C., Quelen C., Meggetto F., Kuhlein E., Delsol G., et al. A novel PAX5-ELN fusion protein identified in B-cell acute lymphoblastic leukemia acts as a dominant negative on wild-type PAX5. Blood 2007, 109:3417-3423.
17. Coyaud E., Struski S., Prade N., Familiades J., Eichner R., Quelen C., et al. Wide diversity of PAX5 alterations in B-ALL: a groupe francophone de cytogenetique hematologique study. Blood 2010, 115:3089-3097.
18. Meyer C., Schneider B., Jakob S., Strehl S., Attarbaschi A., Schnittger S., et al. The MLL recombinome of acute leukemias. Leukemia 2006, 20:777-784.
19. Krivtsov A.V., Armstrong S.A. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer 2007, 7:823-833.
20. Marschalek R. Mechanisms of leukemogenesis by MLL fusion proteins. Br J Haematol 2011, 152:141-154.